demonstrated that Gypenoside XLIX exerts a protective effect against AKI by inhibiting IGFBP7/IGF1R‐mediated inflammation and programmed cell death, suggesting potential avenues for treating AKI [14]. This evidence concerns the gene IGFBP7 and acute kidney injury.